HRP20170267T1 - Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa - Google Patents

Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa Download PDF

Info

Publication number
HRP20170267T1
HRP20170267T1 HRP20170267TT HRP20170267T HRP20170267T1 HR P20170267 T1 HRP20170267 T1 HR P20170267T1 HR P20170267T T HRP20170267T T HR P20170267TT HR P20170267 T HRP20170267 T HR P20170267T HR P20170267 T1 HRP20170267 T1 HR P20170267T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
composition according
angiotensin
aminobutane
disulfandiylbis
Prior art date
Application number
HRP20170267TT
Other languages
English (en)
Croatian (hr)
Inventor
Catherine Llorens-Cortes
Yannick MARC
Ji GAO-DESLIENS
Fabrice Balavoine
Lionel SEGARD
Original Assignee
Quantum Genomics
INSERM (Institut National de la Santé et de la Recherche Médicale)
Centre National De La Recherche Scientifique
College De France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics, INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique, College De France filed Critical Quantum Genomics
Publication of HRP20170267T1 publication Critical patent/HRP20170267T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20170267TT 2011-12-21 2012-12-21 Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa HRP20170267T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306735 2011-12-21
EP12812987.1A EP2793878B1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
PCT/EP2012/076607 WO2013092984A1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Publications (1)

Publication Number Publication Date
HRP20170267T1 true HRP20170267T1 (hr) 2017-05-19

Family

ID=47522577

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170267TT HRP20170267T1 (hr) 2011-12-21 2012-12-21 Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa

Country Status (25)

Country Link
US (1) US10959938B2 (enExample)
EP (1) EP2793878B1 (enExample)
JP (2) JP6212500B2 (enExample)
KR (1) KR20140116879A (enExample)
CN (2) CN104220062B (enExample)
AU (1) AU2012356895B2 (enExample)
BR (1) BR112014015276B1 (enExample)
CA (1) CA2859704C (enExample)
CY (1) CY1118711T1 (enExample)
DK (1) DK2793878T3 (enExample)
EA (1) EA028718B1 (enExample)
ES (1) ES2619027T3 (enExample)
HR (1) HRP20170267T1 (enExample)
HU (1) HUE033403T2 (enExample)
IL (1) IL233156B (enExample)
IN (1) IN2014DN05787A (enExample)
LT (1) LT2793878T (enExample)
MX (1) MX345469B (enExample)
PL (1) PL2793878T3 (enExample)
PT (1) PT2793878T (enExample)
RS (1) RS55774B1 (enExample)
SI (1) SI2793878T1 (enExample)
SM (1) SMT201700156T1 (enExample)
WO (1) WO2013092984A1 (enExample)
ZA (1) ZA201405266B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033403T2 (en) * 2011-12-21 2017-11-28 Quantum Genomics Combination with (3S, 3S ') - 4,4'-disulfandyl-bis (3-aminobutane-1-sulfonic acid) and a second antihypertensive agent
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素-血管收縮素系統阻斷劑之醫藥組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) * 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
AU2003271811A1 (en) * 2002-07-16 2004-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
HUE033403T2 (en) * 2011-12-21 2017-11-28 Quantum Genomics Combination with (3S, 3S ') - 4,4'-disulfandyl-bis (3-aminobutane-1-sulfonic acid) and a second antihypertensive agent

Also Published As

Publication number Publication date
CN109464432A (zh) 2019-03-15
PT2793878T (pt) 2017-03-23
BR112014015276A8 (pt) 2017-06-13
MX2014007547A (es) 2014-08-01
CA2859704A1 (en) 2013-06-27
NZ627251A (en) 2015-08-28
BR112014015276B1 (pt) 2020-09-29
EA201400724A1 (ru) 2014-09-30
CY1118711T1 (el) 2017-07-12
US10959938B2 (en) 2021-03-30
JP6726138B2 (ja) 2020-07-22
HUE033403T2 (en) 2017-11-28
JP2017222696A (ja) 2017-12-21
ES2619027T3 (es) 2017-06-22
RS55774B1 (sr) 2017-07-31
LT2793878T (lt) 2017-05-25
MX345469B (es) 2017-02-01
PL2793878T3 (pl) 2017-08-31
AU2012356895A1 (en) 2014-07-31
HK1203051A1 (en) 2015-10-16
BR112014015276A2 (pt) 2017-06-13
DK2793878T3 (en) 2017-03-27
CN104220062B (zh) 2018-06-15
SMT201700156T1 (it) 2017-05-08
IL233156A0 (en) 2014-07-31
JP6212500B2 (ja) 2017-10-11
WO2013092984A1 (en) 2013-06-27
EP2793878B1 (en) 2017-02-01
ZA201405266B (en) 2016-06-29
AU2012356895B2 (en) 2017-05-25
JP2015506338A (ja) 2015-03-02
CA2859704C (en) 2020-04-28
KR20140116879A (ko) 2014-10-06
SI2793878T1 (sl) 2017-07-31
IN2014DN05787A (enExample) 2015-05-15
EA028718B1 (ru) 2017-12-29
IL233156B (en) 2018-05-31
US20150320703A1 (en) 2015-11-12
CN104220062A (zh) 2014-12-17
EP2793878A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
JP2018507244A5 (enExample)
HRP20150375T1 (hr) Derivati piridazinona
ES2250283T3 (es) Uso de cs-866 (olmesartan) en la preparacion de un medicamento para el tratamiento de la arteriosclerosis.
JP2005532330A5 (enExample)
ME02695B (me) Hinazolinoni kao inhibitori humane fosfatidilonozitol 3- delta kinaze
RU2010123027A (ru) Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep)
TW200306799A (en) Combination of organic compounds
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2007144082A3 (de) Antihypertonie-kombinationswafer
WO2002017913A1 (en) Medicinal compositions for preventing or treating heart failure
RU2020107416A (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
RU2009139186A (ru) Применение гиалуронидазы для профилактики или лечения артериальной гипертензии или сердечной недостаточности
HRP20170267T1 (hr) Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa
ES2622893T3 (es) Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa
JP2002535367A5 (enExample)
RU2006135205A (ru) Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда
CN1271283A (zh) 内皮素拮抗剂和血管紧张肽原酶-血管紧张肽系统抑制剂的药物组合物
JP2006517557A5 (enExample)
RU2539382C2 (ru) Лекарственное средство для лечения гипертензии или повышенного кровяного давления
CA2798573A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
NZ589904A (en) Eprosartan compositions
JP2012254975A (ja) Ace阻害剤とl−アルギニンを含有する医薬組成物